About beam therapeutics inc. - BEAM
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
BEAM At a Glance
Beam Therapeutics, Inc.
238 Main Street
Cambridge, Massachusetts 02142-1016
| Phone | 1-857-327-8775 | Revenue | 377.71M | |
| Industry | Biotechnology | Net Income | -132,527,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 520.008% | |
| Fiscal Year-end | 12 / 2024 | Employees | 436 | |
| View SEC Filings |
BEAM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.56 |
| Price to Book Ratio | 2.264 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.924 |
| Enterprise Value to Sales | 2.868 |
| Total Debt to Enterprise Value | 0.16 |
BEAM Efficiency
| Revenue/Employee | 866,305.046 |
| Income Per Employee | -303,961.009 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.27 |
BEAM Liquidity
| Current Ratio | 5.891 |
| Quick Ratio | 5.891 |
| Cash Ratio | 5.788 |
BEAM Profitability
| Gross Margin | 94.702 |
| Operating Margin | -46.725 |
| Pretax Margin | -34.725 |
| Net Margin | -35.087 |
| Return on Assets | -9.461 |
| Return on Equity | -15.457 |
| Return on Total Capital | -11.479 |
| Return on Invested Capital | -12.964 |
BEAM Capital Structure
| Total Debt to Total Equity | 17.647 |
| Total Debt to Total Capital | 15.00 |
| Total Debt to Total Assets | 11.863 |
| Long-Term Debt to Equity | 16.295 |
| Long-Term Debt to Total Capital | 13.851 |